Bayer
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Bayer sits in the top decile of US sponsors by registered trial count (#58 of 15,742 sponsors by registered trial count).
Bayer: 591 sponsored US clinical trials, 21 recruiting.
Bayer sponsors 591 registered US clinical trials on ClinicalTrials.gov, 21 of them currently recruiting, and 494 completed. 172 of these trials are in Phase 3-4 (later-stage) and 237 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Sunscreening Agents, with 17 trials.
Top-decile sponsor footprint
Bayer ranks in the top decile of sponsors by registered trial count (#58 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
494 of 552 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
591 total, page 12 of 12
BAY12-8039: 5 Days for Sinusitis vs Placebo
NCT00492024
Efficacy and Safety Study in Postmenopausal Women to Determine the Lowest Effective Dose for Relief of Moderate to Severe Hot-Flushes
NCT00206622
Study to Compare the Tolerability and Efficacy of Once Daily Vardenafil vs Vardenafil PRN vs Placebo in Men Immediately After Nerve-sparing Prostatectomy for Improving ED
NCT00492635
Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis
NCT00395772
Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis
NCT00473460
Investigate the Responsiveness of the Erectile Quality Scale to Vardenafil Flexible Dose vs Placebo in Males With Erectile Dysfunction (ED)
NCT00665340
Trial to Evaluate Time to Symptom Relief and Elimination of Infecting Bacteria in Treating Sinusitis With Avelox
NCT00668304
Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro® XR) 1000 mg Tablets Given Once Daily For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas Aeruginosa And Other Common Uropathogens
NCT00481689
BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)
NCT00101413
BAYQ3939, 1000 mg Tablet in Transrectal Needle Biopsies of the Prostate (TRNBP) - Infection Prophylaxis
NCT00670215
An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study
NCT00402467
Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec
NCT00661180
Cardiovascular Safety Study of Magnevist® Injection at Two Dose Levels and Two Injection Rates in Normal Subjects
NCT00310596
Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer
NCT00073307
BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients
NCT00099502
Study to Investigate the Efficacy and Safety of Vardenafil Flexible Dose Versus Placebo in Males With Erectile Dysfunction
NCT00657033
Trial to Evaluate the Efficacy and Safety of Cipro® XR in Treating Female Patients With Lower Urinary Tract Infections
NCT00669994
Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia
NCT00086775
Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis
NCT00235989
A Study to Investigate the Time to Onset of Action of 10 mg and 20 mg of Vardenafil Compared to Placebo in Males With Erectile Dysfunction
NCT00665496
Cipro® XR in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract Infections
NCT00676533
An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS
NCT00206648
STEPS Trial - Spheramine Safety and Efficacy Study
NCT00206687
Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.
NCT00651469
Evaluate Safety and Efficacy of an Oral Contraceptive (OC) Preparation Versus Placebo for 6 Treatment Cycles in Women With Moderate Acne
NCT00656981
Extension Program for Bay 43-9006
NCT00657254
Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection
NCT00059462
Depression Related Improvement With Vardenafil for Erectile Response
NCT00661219
BEYOND Pilot Study
NCT00893217
Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia
NCT00665327
Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer
NCT00079612
A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma
NCT00044512
Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)
NCT00941863
Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma
NCT00044551
Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma
NCT00044564
Evaluation of BAY 59-8862 in Taxane Resistant Non-Small Cell Lung Cancer Patients
NCT00044538
Risk of Acute Liver Injury in Users of Antimicrobials
NCT01434173
Repinotan in Patients With Acute Ischemic Stroke
NCT00044915
Pilot Study of Safety and Efficacy of Spheramine
NCT00761436
BAY 0 9867 Cipro Pediatric Use Study (QUIP)
NCT00761462
Phase III Randomized Double-Blind Placebo Controlled Study To Evaluate the Safety and Efficacy of Betaseron in AIDS and Advanced ARC Patients Receiving a Reduced-Dose AZT Regimen
NCT00002238
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 130 |
| Phase 2 | 107 |
| Phase 3 | 144 |
| Phase 4 | 28 |
What is open in the Bayer pipeline
21 recruiting of 591 indexed (4% open); 494 completed (84%).
Phase mix: 172 late (III/IV) vs 237 early (I/II) (balanced across stages).
Top condition: Sunscreening Agents (17 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Bayer: open-pipeline peers nationwide
Peers matched on 591 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Bayer sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 591 trials (± recruiting share)
- Janssen Research & Development · 593 trials · 11% recruiting
- City of Hope Medical Center · 582 trials · 29% recruiting
- Children's Hospital Medical Center, Cincinnati · 571 trials · 19% recruiting
- National Institute of Neurological Disorders and Stroke (NINDS) · 567 trials · 8% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Bausch Health Americas · 4% recruiting · 168 trials
- Harvard Pilgrim Health Care · 4% recruiting · 28 trials
- Sumitomo Pharma America · 4% recruiting · 168 trials
- Teva Branded Pharmaceutical Products R&D · 4% recruiting · 167 trials
Related
What to do with this Bayer page
591 registered trials is a research-attention snapshot, not an endorsement of Bayer or any single study.
- 21 of Bayer's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Sunscreening Agents is the condition Bayer studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Sunscreening Agents trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Bayer pipeline card: 591 registered trials from official public datasets.Report a data error.